Related Experiment Videos
Autologous stem cell transplantation for malignant lymphomas
Bone Marrow Transplantation
|January 23, 1999
Summary
Autologous stem cell transplantation offers a high survival rate for patients with relapsed lymphoma. This study shows a 90% overall survival and no transplant-related deaths in 20 patients.
Area of Science:
- Hematology
- Oncology
- Transplantation Medicine
Background:
- Relapsed lymphoma presents a significant clinical challenge.
- Chemosensitive relapse indicates potential for treatment response.
- Autologous stem cell transplantation (ASCT) is a consolidative therapy option.
Purpose of the Study:
- To evaluate the efficacy and safety of ASCT in adult patients with relapsed Hodgkin and non-Hodgkin lymphoma.
- To assess overall survival and event-free survival rates post-ASCT.
Main Methods:
- Retrospective analysis of 20 consecutive adult patients with chemosensitive relapsed Hodgkin or non-Hodgkin lymphoma.
- Patients underwent ASCT between December 1995 and April 1998.
- Median follow-up period of 15 months.
Main Results:
- Overall survival rate of 90% (18/20 patients).
- Event-free survival rate of 65% (13/20 patients).
- Zero transplant-related mortality observed.
Conclusions:
- ASCT is a safe and effective treatment for chemosensitive relapsed lymphoma.
- High survival rates support ASCT as a viable therapeutic strategy.
- Further research can explore long-term outcomes and specific lymphoma subtypes.